NEWS & EVENTS
CLEVELAND, Jan. 18, 2017 – Athersys, Inc. (NASDAQ:ATHX) announced today that through its Belgian subsidiary, ReGenesys BVBA (ReGenesys), it has entered into an agreement with a global leader in the animal health business segment to evaluate the cell therapy technology for application in a non-disclosed animal health area. Under the terms of the agreement, ReGenesys will receive an initial payment in exchange for an exclusive period to evaluate the cell therapy technology with an option to negotiate for a license for the development and commercialization of the technology for this area. Additional details were not disclosed.
October 4, 2016 – HoneyLab, the Bay of Plenty-based healthcare company, have today announced that they have entered an exploratory relationship with Procter & Gamble in the USA. HoneyLab co-founder Laurence Greig said that HoneyLab’s strength was developing novel natural products with strong evidence for their effectiveness. He said that rather than building a brand, the aim had always been to partner with companies such as Procter & Gamble. “P&G are one of the biggest consumer companies in the world and we are delighted that our scientifically strong and innovative products have caught the eye of such a prestigious company.”
Lugano, Switzerland and San Diego, USA, August 8, 2016 – Helsinn, a Swiss pharmaceutical group focused on building quality cancer care products, and MEI Pharma, Inc. (Nasdaq: MEIP), an oncology company focused on the clinical development of novel therapies for cancer, today announced that they have entered into an exclusive licensing, development and commercialization agreement for Pracinostat, a Phase III-ready drug candidate for the treatment of acute myeloid leukemia (AML) and other potential indications. The deal provides the complementary resources from both organizations to rapidly advance Pracinostat into Phase III clinical development and expand into additional indications, including high-risk myelodysplastic syndrome (MDS).